Maciej Jurynczyk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4828687/publications.pdf

Version: 2024-02-01

25 2,211 17 24 papers citations h-index g-index

26 26 26 2275
all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain, 2017, 140, 3128-3138.	3.7	527
2	MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e89.	3.1	322
3	Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease. JAMA Neurology, 2018, 75, 478.	4.5	306
4	Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain, 2017, 140, 617-627.	3.7	208
5	Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 132-136.	0.9	132
6	Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis. Journal of Neuroimmunology, 2005, 170, 3-10.	1.1	80
7	Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. Practical Neurology, 2019, 19, 187-195.	0.5	78
8	Immune regulation of multiple sclerosis by transdermally applied myelin peptides. Annals of Neurology, 2010, 68, 593-601.	2.8	74
9	Notch3 Inhibition in Myelin-Reactive T Cells Down-Regulates Protein Kinase CÎ, and Attenuates Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2008, 180, 2634-2640.	0.4	73
10	Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 20-25.	0.9	72
11	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. Journal of Neurology, 2016, 263, 140-149.	1.8	60
12	Notch: A new player in MS mechanisms. Journal of Neuroimmunology, 2010, 218, 3-11.	1.1	58
13	Overcoming failure to repair demyelination in EAE: \hat{I}^3 -secretase inhibition of Notch signaling. Journal of the Neurological Sciences, 2008, 265, 5-11.	0.3	39
14	Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 165-169.	0.9	37
15	Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease. Acta Neuropathologica Communications, 2017, 5, 95.	2.4	35
16	Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 217-227.	1.4	24
17	Natalizumab and the development of extensive brain lesions in neuromyelitis optica. Journal of Neurology, 2013, 260, 1919-1921.	1.8	23
18	Hypoglycemia as a trigger for the syndrome of acute bilateral basal ganglia lesions in uremia. Journal of the Neurological Sciences, 2010, 297, 74-75.	0.3	21

#	Article	IF	CITATIONS
19	Classifying the antibody-negative NMO syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e626.	3.1	17
20	Heat shock protein 70 (Hsp70) interacts with the Notch1 intracellular domain and contributes to the activity of Notch signaling in myelin-reactive CD4 T cells. Journal of Neuroimmunology, 2015, 287, $19-26$.	1.1	7
21	Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD – No. Multiple Sclerosis Journal, 2021, 27, 15-16.	1.4	5
22	Towards imaging criteria that best differentiate MS from NMOSD and MOGAD: large multi-ethnic population and different clinical scenarios. Multiple Sclerosis and Related Disorders, 2022, 61, 103778.	0.9	5
23	Increasing role of imaging in differentiating MS from non-MS and defining indeterminate borderline cases. Neurologia I Neurochirurgia Polska, 2022, 56, 210-219.	0.6	4
24	Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis. Journal of Neurology, 2022, 269, 269-279.	1.8	3
25	EXPERT OPINIONS ON THE DIAGNOSIS AND TREATMENT OF PATIENTS WITH AQP4-NEGATIVE NMO/MS OVERLAPPING SYNDROMES. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.40-e4.	0.9	0